Drugs / Nanoliposomal Irinotecan
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02022644 | Oct 2014 → Dec 2020 | malignant glioma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03785873 | May 2019 → Nov 2024 | biliary tract cancer | University of Michigan Rogel Cancer Center | Completed | Missed primary |
| Phase 24 trials | ||||||
| Phase 2 | NCT06835387 | Jun 2025 → Aug 2027 expected | small intestine adenocarcinoma | Tiago Biachi de Castria | Recruiting | No outcome recorded |
| Phase 2 | NCT06405490 | Apr 2024 → Aug 2026 overdue | pancreatic adenocarcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05472259 | May 2022 → Dec 2026 expected | pancreatic ductal adenocarcinoma | Belgian Group of Digestive Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT04005339 | Jul 2019 → Sep 2025 overdue | biliary tract cancer | Georgetown University | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06219941 Background | Dec 2023 → Aug 2026 overdue | biliary tract cancer, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanoliposomal irinotecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05472259 ↗ |
| Route | Other | “given by intra tumoral real-time convection enhanced delivery” NCT02022644 ↗ |